AJN003 Platform
Obesity / Weight Management
Key Facts
About AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profileAbout AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profileAbout AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profileAbout AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profileAbout AltrixBio
AltrixBio is pioneering a new category of metabolic therapeutics with its lead candidate, AJN003, a once-daily oral pill that mimics the distal nutrient shift of gastric bypass surgery. Founded by a team with deep clinical and scientific expertise, the company leverages a bio-engineered compound derived from sucralfate, aiming to deliver glycemic control and weight loss without systemic absorption. With strong pre-clinical data, a clear regulatory strategy, and a platform with potential applications beyond diabetes, AltrixBio is positioned to address significant unmet needs in the growing obesity and metabolic disease markets.
View full company profile